Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing ...
Zacks.com on MSN6h
Amgen Stock Falls 12% in a Month: Should You Buy the Dip?AMGN's reasonable valuation, an interesting pipeline and continued top-line growth are good enough reasons to stay invested ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...
According to phase 2 study, MariTide achieved significant weight loss in individuals with obesity or overweight, with up to ...
Versant is out with its third obesity biotech of the year, leading an €80 million Series A for Antag Therapeutics, a Danish ...
Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.
The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...
Amgen's experimental weight loss injection, MariTide, showed up to 20% weight loss in patients without diabetes and 17% in ...
Top-line phase 2 results with Amgen's MariTide drug for obesity are finally in – but the highly anticipated doesn't seem to have lived up to investor expectations. MariTide (maridebart ...
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback